News

Alan H. Bryce, MD, discusses areas of need to help guide treatment decisions in the clinic for prostate cancer management.

Tilsotolimod plus ipilimumab did not show benefit vs ipilimumab alone in anti–PD-1 refractory melanoma, despite prior positive phase 1/2 trial data.

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell lymphoma.

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders.

Paul B. Renz, DO, discusses anecdotal changes observed by clinician researchers using the MR-LINAC system.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

The FDA has cleared EVM14, making it the first mRNA therapeutic cancer vaccine for global clinical trials.

Paul B. Renz, DO, discusses the ideal uses of magnetic resonance-guided linear accelerator system.

For Nutrition Awareness Month, we highlight the importance of tailoring dietary strategies to patients with cancer to improve outcomes and quality of life.

Hedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology.

Positive data and developments to be aware of in AML, breast cancer, PDAC, and NMIBC.

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Rodabe Amaria, MD, discusses the current role of OBX-115 for the treatment of patients with checkpoint inhibitor-resistant metastatic melanoma.

Investigators found that higher persistent PSA levels after surgery were linked to a worse prognosis, underscoring the importance of timing in post-operative care.

With changes in demographics and advancements in cancer care, the current oncologist workforce is expected to experience an imbalance in supply and demand.

Wojciech Jurczak, MD, PhD, ​​discusses nemtabrutinib and its development for the treatment of follicular lymphoma.

PEP-010 was granted FDA orphan drug designation for the treatment of pancreatic cancer.

TLX007-CDx is now an FDA-approved PSMA PET imaging agent in prostate cancer.

The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected after the first quarter of 2025.

ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid tumors.

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or higher.

The anti–PD-1/VEGF combination of pembrolizumab and bevacizumab elicited strong clinical activity in patients with melanoma brain metastases.

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint inhibitor-resistant metastatic melanoma.

The combination of pembrolizumab, trastuzumab, and chemotherapy is now approved in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line treatment.

Tarlatamab showed a positive benefit-risk profile in small cell lung cancer, per the phase 2 DeLLphi-301 study.

A phase 3 trial plans to evaluate Pro-ocular for the treatment of patients with ocular graft-vs-host disease.